-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 23rd, local time, the Chilean Institute of Public Health approved the minimum vaccination age for the emergency use of SINOVAC’s new crown vaccine Kelefort from three years old to six months.
Children need to be vaccinated with two doses of Kelefu, with an interval between vaccinations.
14-28 days
.
This is another approval for children over the age of 6 months after the first approval for use in children over 6 months in Hong Kong, China earlier this month
.
Up to now, Kexing's new crown vaccine Kellev is the only new crown inactivated vaccine approved for 6-month-old children in the world
.
Children need to be vaccinated with two doses of Kelefu, with an interval between vaccinations.
14-28 days
.
This is another approval for children over the age of 6 months after the first approval for use in children over 6 months in Hong Kong, China earlier this month
.
Up to now, Kexing's new crown vaccine Kellev is the only new crown inactivated vaccine approved for 6-month-old children in the world
.
It is reported that SINOVAC will start a multi-center, randomized, double-blind, placebo-controlled Phase III clinical study in South Africa, Chile, Malaysia, the Philippines and other countries in 2021 in healthy
people aged 6 months to 17 years old .
Studies have shown that Clarifol has good safety and immunogenicity in children aged 6-35 months, and children aged 6-35 months who were previously infected have no serious adverse reactions when vaccinated with Clarifol , and it can induce more severe adverse reactions.
High neutralizing antibody levels
.
people aged 6 months to 17 years old .
Studies have shown that Clarifol has good safety and immunogenicity in children aged 6-35 months, and children aged 6-35 months who were previously infected have no serious adverse reactions when vaccinated with Clarifol , and it can induce more severe adverse reactions.
High neutralizing antibody levels
.
It is understood that as of now, Kexing’s new crown vaccine has been approved for vaccination of children and adolescents in 14 countries and regions including Indonesia, Thailand, Brazil, Chile, Colombia, etc.
, with a total of more than 260 million doses of vaccinations, a total of over 130 million vaccines in the world.
Adults provide protection against COVID-19
.
, with a total of more than 260 million doses of vaccinations, a total of over 130 million vaccines in the world.
Adults provide protection against COVID-19
.
On August 23rd, local time, the Chilean Institute of Public Health approved the minimum vaccination age for the emergency use of SINOVAC’s new crown vaccine Kelefort from three years old to six months.
Children need to be vaccinated with two doses of Kelefu, with an interval between vaccinations.
14-28 days
.
This is another approval for children over the age of 6 months after the first approval for use in children over 6 months in Hong Kong, China earlier this month
.
Up to now, Kexing's new crown vaccine Kellev is the only new crown inactivated vaccine approved for 6-month-old children in the world
.
Children need to be vaccinated with two doses of Kelefu, with an interval between vaccinations.
14-28 days
.
This is another approval for children over the age of 6 months after the first approval for use in children over 6 months in Hong Kong, China earlier this month
.
Up to now, Kexing's new crown vaccine Kellev is the only new crown inactivated vaccine approved for 6-month-old children in the world
.
It is reported that SINOVAC will start a multi-center, randomized, double-blind, placebo-controlled Phase III clinical study in South Africa, Chile, Malaysia, the Philippines and other countries in 2021 in healthy
people aged 6 months to 17 years old .
Studies have shown that Clarifol has good safety and immunogenicity in children aged 6-35 months, and children aged 6-35 months who were previously infected have no serious adverse reactions when vaccinated with Clarifol , and it can induce more severe adverse reactions.
High neutralizing antibody levels
.
healthy children adverse reactions adverse reactionspeople aged 6 months to 17 years old .
Studies have shown that Clarifol has good safety and immunogenicity in children aged 6-35 months, and children aged 6-35 months who were previously infected have no serious adverse reactions when vaccinated with Clarifol , and it can induce more severe adverse reactions.
High neutralizing antibody levels
.
It is understood that as of now, Kexing’s new crown vaccine has been approved for vaccination of children and adolescents in 14 countries and regions including Indonesia, Thailand, Brazil, Chile, Colombia, etc.
, with a total of more than 260 million doses of vaccinations, a total of over 130 million vaccines in the world.
Adults provide protection against COVID-19
.
, with a total of more than 260 million doses of vaccinations, a total of over 130 million vaccines in the world.
Adults provide protection against COVID-19
.
![9-[3-Chloro-5-(phenanthren-9-yl)phenyl]phenanthrene / 1369431-34-4](https://file.echemi.com/fileManage/upload/goodpicture/20241028/9-3-chloro-5-phenanthren-9-ylphenylphenanthrene-1369431-34-4_b20241028151130118.jpg)
